328 related articles for article (PubMed ID: 16236092)
1. Focus on trial endpoints of clinical relevance and the use of almotriptan for the acute treatment of migraine.
Sandrini G; Dahlöf CG; Mathew N; Nappi G
Int J Clin Pract; 2005 Nov; 59(11):1356-65. PubMed ID: 16236092
[TBL] [Abstract][Full Text] [Related]
2. Early intervention with almotriptan: results of the AEGIS trial (AXERT Early Migraine Intervention Study).
Mathew NT; Finlayson G; Smith TR; Cady RK; Adelman J; Mao L; Wright P; Greenberg SJ;
Headache; 2007 Feb; 47(2):189-98. PubMed ID: 17300358
[TBL] [Abstract][Full Text] [Related]
3. Use of the sustained pain-free plus no adverse events endpoint in clinical trials of triptans in acute migraine.
Dodick DW; Sandrini G; Williams P
CNS Drugs; 2007; 21(1):73-82. PubMed ID: 17190530
[TBL] [Abstract][Full Text] [Related]
4. Almotriptan improves response rates when treatment is within 1 hour of migraine onset.
Dowson AJ; Massiou H; Lainez JM; Cabarrocas X
Headache; 2004 Apr; 44(4):318-22. PubMed ID: 15109355
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of almotriptan 12.5 mg in achieving migraine-related composite endpoints: a double-blind, randomized, placebo-controlled study in patients controlled study in patients with previous poor response to sumatriptan 50 mg.
Diener HC
Curr Med Res Opin; 2005 Oct; 21(10):1603-10. PubMed ID: 16238900
[TBL] [Abstract][Full Text] [Related]
6. Almotriptan and zolmitriptan in the acute treatment of migraine.
Goadsby PJ; Massiou H; Pascual J; Diener HC; Dahlöf CG; Mateos V; Dowson AJ; Raets I; Cunha L; Färkkilä M; Manzoni GC
Acta Neurol Scand; 2007 Jan; 115(1):34-40. PubMed ID: 17156263
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, speed of action and tolerability of almotriptan in the acute treatment of migraine: pooled individual patient data from four randomized, double-blind, placebo-controlled clinical trials.
Dahlöf CG; Pascual J; Dodick DW; Dowson AJ
Cephalalgia; 2006 Apr; 26(4):400-8. PubMed ID: 16556240
[TBL] [Abstract][Full Text] [Related]
8. Almotriptan for the treatment of acute migraine: a review of early intervention trials.
Antonaci F; De Cillis I; Cuzzoni MG; Allena M
Expert Rev Neurother; 2010 Mar; 10(3):351-64. PubMed ID: 20187858
[TBL] [Abstract][Full Text] [Related]
9. Almotriptan: a review of pharmacology, clinical efficacy, and tolerability.
Von S
Am J Manag Care; 2002 Feb; 8(3 Suppl):S74-9. PubMed ID: 11859907
[TBL] [Abstract][Full Text] [Related]
10. The 'Act when Mild' (AwM) study: a step forward in our understanding of early treatment in acute migraine.
Goadsby PJ
Cephalalgia; 2008 Sep; 28 Suppl 2():36-41. PubMed ID: 18715331
[TBL] [Abstract][Full Text] [Related]
11. Oral almotriptan: practical uses in the acute treatment of migraine.
Dowson AJ
Expert Rev Neurother; 2004 May; 4(3):339-48. PubMed ID: 15853532
[TBL] [Abstract][Full Text] [Related]
12. How treatment priorities influence triptan preferences in clinical practice: perspectives of migraine sufferers, neurologists, and primary care physicians.
Lipton RB; Cutrer FM; Goadsby PJ; Ferrari MD; Dodick DW; McCrory D; Liberman JN; Williams P
Curr Med Res Opin; 2005 Mar; 21(3):413-24. PubMed ID: 15811210
[TBL] [Abstract][Full Text] [Related]
13. Use of almotriptan in triptan-experienced and triptan-naïve patients.
Pascual J; Diener HC
Curr Med Res Opin; 2007 Oct; 23(10):2433-40. PubMed ID: 17723158
[TBL] [Abstract][Full Text] [Related]
14. Effect of pain intensity and time to administration on responsiveness to almotriptan: results from AXERT 12.5 mg Time Versus Intensity Migraine Study (AIMS).
Freitag FG; Finlayson G; Rapoport AM; Elkind AH; Diamond ML; Unger JR; Fisher AC; Armstrong RB; Hulihan JF; Greenberg SJ;
Headache; 2007 Apr; 47(4):519-30. PubMed ID: 17445101
[TBL] [Abstract][Full Text] [Related]
15. Using patient-centered endpoints to determine the cost-effectiveness of triptans for acute migraine therapy.
Kelman L; Von Seggern RL
Am J Ther; 2006; 13(5):411-7. PubMed ID: 16988536
[TBL] [Abstract][Full Text] [Related]
16. Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial.
Diener HC; Gendolla A; Gebert I; Beneke M
Headache; 2005; 45(7):874-82. PubMed ID: 15985104
[TBL] [Abstract][Full Text] [Related]
17. Eletriptan for the acute treatment of migraine in adolescents: results of a double-blind, placebo-controlled trial.
Winner P; Linder SL; Lipton RB; Almas M; Parsons B; Pitman V
Headache; 2007 Apr; 47(4):511-8. PubMed ID: 17445100
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of almotriptan in postmarketing surveillance studies.
Pascual J
Eur Neurol; 2005; 53 Suppl 1():34-40. PubMed ID: 15920336
[TBL] [Abstract][Full Text] [Related]
19. Time to pain freedom and onset of pain relief with rizatriptan 10 mg and prescription usual-care oral medications in the acute treatment of migraine headaches: a multicenter, prospective, open-label, two-attack, crossover study.
Bell CF; Foley KA; Barlas S; Solomon G; Hu XH
Clin Ther; 2006 Jun; 28(6):872-80. PubMed ID: 16860170
[TBL] [Abstract][Full Text] [Related]
20. Almotriptan: meeting today's needs in acute migraine treatment.
Láinez MJ
Expert Rev Neurother; 2007 Dec; 7(12):1659-73. PubMed ID: 18052762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
